Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

• FDA label_change · 2018-03-22
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for TASIGNA (nilotinib) from Novartis to update the drug's label.

• FDA label_change · 2016-08-31
  FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

  The FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) by Takeda Pharmaceuticals America, Inc., resulting in labe…